Kairos Pharma, LTD. (KAPA) — 10-Q Filings
All 10-Q filings from Kairos Pharma, LTD.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
Kairos Pharma's Net Loss Widens to $4.08M Amid Soaring R&D Costs
— Nov 14, 2025 Risk: high
Kairos Pharma, LTD. (KAPA) reported a net loss of $4.082 million for the nine months ended September 30, 2025, a significant increase from the $1.623 million ne -
Kairos Pharma's Losses Mount Amid R&D Surge, Secures Fresh Capital
— Aug 12, 2025 Risk: high
Kairos Pharma, LTD. (KAPA) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $2,684,000, a substantial rise from the -
Kairos Pharma Files Q1 2025 10-Q
— May 14, 2025 Risk: low
Kairos Pharma, LTD. filed its 10-Q for the period ending March 31, 2025. The company, located in Los Angeles, CA, operates in the Pharmaceutical Preparations se -
Kairos Pharma Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Kairos Pharma, LTD. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware and operating in the pharmaceutical preparati
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX